An interventional study of POPMETRE® (Axelife , France) in Diabetes, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.
Among the 352 studies in Diabetes Mellitus with a site in France, this one is the 147th largest by planned enrollment of the 242 interventional ones that give a count, is one of 10 that started in 2023, is one of 100 with no phase, reaches primary completion later than 23 of the 51 other live ones, and was the 312th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18–80
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
Insulet Corporation · Sites in France
Ages 2+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
352 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 32 · Phase 3 83 · Phase 4 27
First in 1990; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 187 across the 242 interventional studies, 268 across the 110 observational. Of the 263 that completed or were terminated, 71 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 352 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.
Centre Hospitalier Universitaire de Nice has 5 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455994Centre Hospitalier Universitaire de Saint EtienneDysautonomia in Children With Type 1 Diabetes | 2026-12 |
| NCT05795582Centre Hospitalier Universitaire de NiceUpstroke Time Measured by Photoplethysmography | 2026-12-14 |
| NCT06782997CHU de ReimsPerformance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy. | 2026-12-17 |
| NCT06066801Assistance Publique - Hôpitaux de ParisBedside Bone Biopsy in Diabetic Foot Osteomyelitis | 2027-03 |
| NCT07910721SolsiusContinuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. | 2027-04-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 352 studies in Diabetes Mellitus with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Peripherial arterial disease (PAD) and diabetes are major public health issues. In 2020, according to the latest epidemiological data, it is estimated that there will be more than one million patients with PAD and more than 3.5 million diabetic patients in France.
In the diabetic patient, screening for PAD is carried out by calculating the Toe-Brachial pressure index (TBi), a technique that remains time-consuming and technically demanding, which limits its use for clinical routine screening.
A new photoplethysmographic method (PPG) makes possible to determine the quality of peripheral perfusion thanks to the automatic computation of the upstroke time (TMS in ms).
This method appears to be a promising, inexpensive, faster and easier technical alternative to improve the dissemination of the vascular screening in diabetics.
To date, no prospective study has established a relationship between the measurement of upstroke time using the PPG method and TBi in a specific diabetic population.We will perform a two-centre prospective study (Nice University Hospital and Antibes Hospital) comparing the two techniques. The main objective of our study will compare the values of the upstroke time obtained by a PPG method and the TBi in a population of diabetic patients.
The secondary objectives will be to compare the TBi values to the ratio of the TMS measurements at the toe to the reference TMS measured at the hand and to determine the sensitivity-specificity of the TMS measured by PPG compared to the TBi in the detection of a significant PAD in diabetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be included during a vascular medicine consultation for follow-up or screening for vascular pathology. Each subject will have their upstroke time measured by a new method of measurement using the device POPMETRE® (Axelife, France).
Device: POPMETRE® (Axelife , France)
Measurement with 2 devices
Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo
TMS measurement
Time frame: 1 hour
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 42 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice →